LIPIGON PHARMACEUTICALS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2795 SEK | +1.08% |
|
-10.27% | -35.15% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 15.99 | 54.49 | 35.34 | - | - |
| Enterprise Value (EV) 1 | 15.99 | 22.56 | 15.74 | 35.34 | 35.34 |
| P/E ratio | - | - | - | - | - |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 41 x | 3.12 x | 2.39 x | 1.32 x | 0.36 x |
| EV / Revenue | 41 x | 1.29 x | 1.06 x | 1.32 x | 0.36 x |
| EV / EBITDA | -0.42 x | -1.83 x | -0.85 x | -1.4 x | 0.5 x |
| EV / FCF | -426,858 x | - | - | - | - |
| FCF Yield | -0% | - | - | - | - |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 20,244 | 126,422 | 126,422 | - | - |
| Reference price 2 | 0.7900 | 0.4310 | 0.2795 | 0.2795 | 0.2795 |
| Announcement Date | 23-02-28 | 24-02-22 | - | - | - |
1SEK in Million2
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | 4.278 | 0.39 | 17.48 | 14.8 | 26.8 | 97.7 |
| EBITDA 1 | - | -38.11 | -12.35 | -18.6 | -25.2 | 70.2 |
| EBIT 1 | - | -37.74 | -12.37 | -18.6 | -25.2 | 70.2 |
| Operating Margin | - | -9,677.44% | -70.77% | -125.68% | -94.03% | 71.85% |
| Earnings before Tax (EBT) 1 | - | -37.7 | -12.13 | -18.6 | -25.2 | - |
| Net income 1 | -8.068 | -37.7 | -12.13 | -18.6 | -25.2 | - |
| Net margin | -188.59% | -9,667.95% | -69.38% | -125.68% | -94.03% | - |
| EPS | - | - | - | - | - | - |
| Free Cash Flow | - | -37.47 | - | - | - | - |
| FCF margin | - | -9,606.92% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 21-04-30 | 23-02-28 | 24-02-22 | - | - | - |
1SEK in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 31.9 | 19.6 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | -37.5 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 21-04-30 | 23-02-28 | 24-02-22 | - | - | - |
1SEK in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -35.15% | 3.26M | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- LPGO Stock
- Financials Lipigon Pharmaceuticals AB